A national therapy project for drug resistant pulmonary tuberculosis.
D000328:Adult; D000368:Aged; D002207:Capreomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009664:Norway; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D000637:Transaminases / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced
D002207:Capreomycin; D004977:Ethambutol; D003404:Creatinine; D000637:Transaminases; D012293:Rifampin